These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy of 5HT in migraine. Buzzi MG Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654 [No Abstract] [Full Text] [Related]
3. Is a central action of acute antimigraine drugs essential? Goadsby PJ Cephalalgia; 1997 Jun; 17 Suppl 17():10-1. PubMed ID: 9218879 [No Abstract] [Full Text] [Related]
4. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Cumberbatch MJ; Hill RG; Hargreaves RJ Eur J Pharmacol; 1998 Nov; 362(1):43-6. PubMed ID: 9865528 [TBL] [Abstract][Full Text] [Related]
5. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices. Stepień A; Chalimoniuk M; Strosznajder J Cephalalgia; 1999 Dec; 19(10):859-65. PubMed ID: 10668104 [TBL] [Abstract][Full Text] [Related]
6. Measuring central action of acute antimigraine drugs in humans. Schoenen J Cephalalgia; 1997 Jun; 17 Suppl 17():12-5; discussion 15-6. PubMed ID: 9218880 [No Abstract] [Full Text] [Related]
7. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. Deleu D; Hanssens Y J Clin Pharmacol; 2000 Jul; 40(7):687-700. PubMed ID: 10883409 [TBL] [Abstract][Full Text] [Related]
8. Effects of zolmitriptan (Zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. Hughes AM; Dixon R; Dane A; Kemp J; Cummings L; Yates RA Cephalalgia; 1999 Mar; 19(2):100-6; discussion 73. PubMed ID: 10214535 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of the 5-HT1B/1D receptor agonists. Tepper SJ; Rapoport AM; Sheftell FD Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355 [TBL] [Abstract][Full Text] [Related]
10. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Nilsson T; Longmore J; Shaw D; Pantev E; Bard JA; Branchek T; Edvinsson L Eur J Pharmacol; 1999 May; 372(1):49-56. PubMed ID: 10374714 [TBL] [Abstract][Full Text] [Related]
14. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Deleu D; Hanssens Y Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351 [TBL] [Abstract][Full Text] [Related]
15. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine. MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508 [TBL] [Abstract][Full Text] [Related]
17. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Proietti-Cecchini A; Afra J; Schoenen J Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273 [TBL] [Abstract][Full Text] [Related]
18. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Ferrari MD Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266 [TBL] [Abstract][Full Text] [Related]
19. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group. Zagami AS Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor. Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]